Muhiddin A Ozkor1, Ayaz M Rahman1, Jonathan R Murrow1, Nino Kavtaradze1, Ji Lin1, Amita Manatunga1, Salim Hayek1, Arshed A Quyyumi2. 1. From the Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA (M.A.O., A.M.R., J.R.M., N.K., S.H., A.A.Q.); and Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA (J.L., A.M.). 2. From the Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA (M.A.O., A.M.R., J.R.M., N.K., S.H., A.A.Q.); and Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA (J.L., A.M.). aquyyum@emory.edu.
Abstract
OBJECTIVE: Abnormalities in nitric oxide (NO) bioavailability have been reported in blacks. Whether there are differences in endothelium-derived hyperpolarizing factor (EDHF) in addition to NO between blacks and whites and how these affect physiological vasodilation remain unknown. We hypothesized that the bioavailability of vascular NO and EDHF, at rest and with pharmacological and physiological vasodilation, varies between whites and blacks. APPROACH AND RESULTS: In 74 white and 86 black subjects without known cardiovascular disease risk factors, forearm blood flow was measured using plethysmography at rest and during inhibition of NO with N(G)-monomethyl-L-arginine and of K(+) Ca channels (EDHF) with tetraethylammonium. The reduction in resting forearm blood flow was greater with N(G)-monomethyl-L-arginine (P=0.019) and similar with tetraethylammonium in whites compared with blacks. Vasodilation with bradykinin, acetylcholine, and sodium nitroprusside was lower in blacks compared with whites (all P<0.0001). Inhibition with N(G)-monomethyl-L-arginine was greater in whites compared with blacks with bradykinin, acetylcholine, and exercise. Inhibition with tetraethylammonium was lower in blacks with bradykinin, but greater during exercise and with acetylcholine. CONCLUSIONS: The contribution to both resting and stimulus-mediated vasodilator tone of NO is greater in whites compared with blacks. EDHF partly compensates for the reduced NO release in exercise and acetylcholine-mediated vasodilation in blacks. Preserved EDHF but reduced NO bioavailability and sensitivity characterizes the vasculature in healthy blacks. CLINICAL TRIAL REGISTRATION URL: http://clinicaltrials.gov/. Unique identifier: NCT00166166.
OBJECTIVE: Abnormalities in nitric oxide (NO) bioavailability have been reported in blacks. Whether there are differences in endothelium-derived hyperpolarizing factor (EDHF) in addition to NO between blacks and whites and how these affect physiological vasodilation remain unknown. We hypothesized that the bioavailability of vascular NO and EDHF, at rest and with pharmacological and physiological vasodilation, varies between whites and blacks. APPROACH AND RESULTS: In 74 white and 86 black subjects without known cardiovascular disease risk factors, forearm blood flow was measured using plethysmography at rest and during inhibition of NO with N(G)-monomethyl-L-arginine and of K(+) Ca channels (EDHF) with tetraethylammonium. The reduction in resting forearm blood flow was greater with N(G)-monomethyl-L-arginine (P=0.019) and similar with tetraethylammonium in whites compared with blacks. Vasodilation with bradykinin, acetylcholine, and sodium nitroprusside was lower in blacks compared with whites (all P<0.0001). Inhibition with N(G)-monomethyl-L-arginine was greater in whites compared with blacks with bradykinin, acetylcholine, and exercise. Inhibition with tetraethylammonium was lower in blacks with bradykinin, but greater during exercise and with acetylcholine. CONCLUSIONS: The contribution to both resting and stimulus-mediated vasodilator tone of NO is greater in whites compared with blacks. EDHF partly compensates for the reduced NO release in exercise and acetylcholine-mediated vasodilation in blacks. Preserved EDHF but reduced NO bioavailability and sensitivity characterizes the vasculature in healthy blacks. CLINICAL TRIAL REGISTRATION URL: http://clinicaltrials.gov/. Unique identifier: NCT00166166.
Authors: N Gokce; M Holbrook; S J Duffy; S Demissie; L A Cupples; E Biegelsen; J F Keaney; J Loscalzo; J A Vita Journal: Hypertension Date: 2001-12-01 Impact factor: 10.190
Authors: Alanna A Morris; Liping Zhao; Riyaz S Patel; Dean P Jones; Yusuf Ahmed; Neli Stoyanova; Gary H Gibbons; Viola Vaccarino; Rebecca Din-Dzietham; Arshed A Quyyumi Journal: Metab Syndr Relat Disord Date: 2012-03-02 Impact factor: 1.894
Authors: Brett J Wong; Casey G Turner; James T Miller; Demetria C Walker; Yesser Sebeh; Matthew J Hayat; Jeffrey S Otis; Arshed A Quyyumi Journal: Am J Physiol Heart Circ Physiol Date: 2020-06-19 Impact factor: 4.733
Authors: Huimin Yan; Sushant M Ranadive; Abbi D Lane-Cordova; Rebecca M Kappus; Michael A Behun; Marc D Cook; Jeffrey A Woods; Kenneth R Wilund; Tracy Baynard; John R Halliwill; Bo Fernhall Journal: J Appl Physiol (1985) Date: 2016-12-15
Authors: Jennifer R Vranish; Seth W Holwerda; Benjamin E Young; Daniel P Credeur; Jordan C Patik; Thales C Barbosa; David M Keller; Paul J Fadel Journal: Hypertension Date: 2017-12-04 Impact factor: 10.190
Authors: A E Schutte; S Botha; C M T Fourie; L F Gafane-Matemane; R Kruger; L Lammertyn; L Malan; C M C Mels; R Schutte; W Smith; J M van Rooyen; L J Ware; H W Huisman Journal: J Hum Hypertens Date: 2017-03-23 Impact factor: 3.012
Authors: Elizabeth C Schroeder; Sushant M Ranadive; Huimin Yan; Abbi D Lane-Cordova; Rebecca M Kappus; Marc D Cook; Bo Fernhall Journal: J Hypertens Date: 2019-06 Impact factor: 4.844
Authors: Stephen J Carter; TaShauna U Goldsby; Gordon Fisher; Eric P Plaisance; Barbara A Gower; Stephen P Glasser; Gary R Hunter Journal: Appl Physiol Nutr Metab Date: 2016-01-07 Impact factor: 2.665
Authors: Heather M Prendergast; Samuel Dudley; Michael Brown; Martha Daviglus; John Kane; E Bradshaw Bunney; Jared Marcucci; Rasheed Sanyaolu Journal: High Blood Press Cardiovasc Prev Date: 2014-06-28